Results 101 to 110 of about 5,545 (148)

Real-world impact of mepolizumab on pediatric and adolescent patients with severe asthma

open access: yesJournal of Allergy and Clinical Immunology: Global
Background: Real-world evidence on the effectiveness of mepolizumab in children and adolescents with severe asthma (SA) is limited. Objective: We sought to evaluate mepolizumab’s impact on the clinical and health care resource utilization (HCRU) burden ...
Michelle L. Hernandez, MD   +6 more
doaj   +1 more source

Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)

open access: yesJournal of Asthma and Allergy, 2023
Stephanie Korn,1 Katrin Milger,2 Dirk Skowasch,3 Christian Schulz,4 Cordula Mohrlang,5 Martin Wernitz,5 Thomas Paulsson,6 Michael Hennig,5 Roland Buhl7 1IKF Pneumologie Mainz, Mainz and Thoraxklinik Heidelberg, Heidelberg, Germany; 2Department of ...
Korn S   +8 more
doaj  

Mepolizumab for the management of chronic rhinosinusitis with nasal polyps across the United States: A retrospective study

open access: yesJournal of Allergy and Clinical Immunology: Global
Background: Retrospective data are limited on the effectiveness of mepolizumab treatment that is reflective of real-world practice in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Juan Carlos Cardet, MD, MPH   +10 more
doaj   +1 more source

Genes and Pathways Regulating Decline in Lung Function and Airway Remodeling in Asthma. [PDF]

open access: yes, 2019
Asthma is a common disorder of the airways characterized by airway inflammation and by decline in lung function and airway remodeling in a subset of asthmatics.
Broide, David H, Hur, Gyu Young
core  

Improved long-term prognosis of eosinophilic granulomatosis with polyangiitis: retrospective analysis of 87 patients after biologic therapy introduction in Japan

open access: yesScientific Reports
Five-year survival in eosinophilic granulomatosis with polyangiitis (EGPA) exceeds 90%, but long-term prognosis is poor. We examined prognosis in 87 Japanese EGPA patients, seen between April 2018 and December 2024, after mepolizumab introduction ...
Yuga Yamashita   +11 more
doaj   +1 more source

Poliangeitis amb Granulomatosis eosinofílica i asma al·lèrgica; dues monedes amb una mateixa cara? [PDF]

open access: yes, 2013
La síndrome de Churg-Strauss o Poliangeitis amb Granulomatosis eosinofílica (EGPA), clàssicament s'ha vinculat a un substrat asmàtic d'origen al·lèrgic. No obstant, l'evidència en aquest sentit és equívoca.
Bosch Gil, Josep Àngel   +4 more
core  

Eosinophile Ösophagitis: Die Sicht des Gastroenterologen [PDF]

open access: yes, 2018
Zusammenfassung: Die eosinophile Ösophagitis ist charakterisiert durch Symptome ösophagealer Dysfunktion (meist Dysphagie) und eosinophile Entzündungsinfiltrate im Ösophagus.
Schoepfer, A.
core  

Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma

open access: yesJournal of Asthma and Allergy, 2020
Jared Silver,1 Michael Bogart,1 Elizabeth Packnett,2 Juan Wu,2 Donna McMorrow,2 Beth Hahn1 1US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2Life Sciences, IBM Watson Health, Bethesda, MD, USACorrespondence: Beth Hahn Email beth.a.hahn@gsk ...
Silver J   +5 more
doaj  

Immunoteràpia, un concepte clàssic amb novetats rellevants: els biològics i la immunoteràpia antitumoral com a exemples concrets [PDF]

open access: yes, 2014
De la inducció de memòria immunitària de les vacunes antiinfeccioses, a la immunoteràpia cel·lular i genètica per al tractament de tumors, el ventall de teràpies potencials a través de la modulació del sistema immunitari és una de les aproximacions més ...
Caballero Baños, Miguel   +3 more
core  

Home - About - Disclaimer - Privacy